Skip to main content
Fig. 6 | Cardiovascular Diabetology

Fig. 6

From: The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial

Fig. 6

a Fat free mass (kg) show that the saxagliptin group had a sharp decline after visit 1, but then a rise after visit 2, and the placebo group remained relatively stable (0.072). b  % Body Fat across visits 1–3. Saxagliptin patients had a decline from visit 1 to 3, whereas the control group increased at visit 3 (p = 0.079). c % total body water remained relatively stable for the placebo group, but increase in saxagliptin (p = 0.098)

Back to article page